HNWAG
KROS icon

High Net Worth Advisory Group’s Keros Therapeutics KROS Stock Holding History

High Net Worth Advisory Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$14K – 703
2022
Q2 		$14K Hold
500
– – 0.01% 496
2022
Q1 		$27K Hold
500
– – 0.01% 414
2021
Q4 		$29K Buy
+500
New +$24.9K 0.01% 411

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

High Net Worth Advisory Group's KROS Position: Q3 2022 in Review

High Net Worth Advisory Group sold out of Keros Therapeutics (KROS) in Q3 2022, closing a stake of 500 shares — an estimated $14K sold.

High Net Worth Advisory Group first reported a position in KROS in Q4 2021 and held it in 3 quarters. The position peaked at $29K in Q4 2021. 113 funds tracked by Wall St. Rank hold KROS as of Q3 2022.

  • High Net Worth Advisory Group reported no remaining Keros Therapeutics position as of Q3 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 500 Keros Therapeutics shares in Q3 2022, an estimated $14K.
  • High Net Worth Advisory Group first reported a position in Keros Therapeutics in Q4 2021 and held it in 3 quarters.
  • High Net Worth Advisory Group's Keros Therapeutics position peaked at $29K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2022.

Based on High Net Worth Advisory Group's 13F filing for Q3 2022, filed 24 Oct 2022.